A recent study in Nature Medicine highlights a multiomics approach combining spatial single-cell proteomics, which significantly enhances treatment decision-making for patients with late-stage melanoma. This innovative method led to a three-fold increase in progression-free survival compared to standard treatments. The study team, including experts like Stéphane Chevrier and Andreas Wicki, addressed logistical challenges and demonstrated the potential of advanced biomarker selection for personalized therapy, while emphasizing the importance of drug access and reimbursement in integrating such diagnostics into routine care.
Newsletters
Receive the latest pathologist news, personalities, education, and career development – weekly to your inbox.